Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog.
BACKGROUND
Ischemia-reperfusion injury with the resulting inflammatory response is a devastating complication of lung transplantation; much of the tissue damage could be diminished by control of the inflammatory response. Recent studies have show that antithrombin III (AT III) has an anti-inflammatory effect in addition to its established role in the regulation of blood coagulation. Thus, we hypothesized that the administration of AT III might help to prevent ischemia-reperfusion injury after lung transplantation.


RESULTS
The study was performed in a dog model of orthotopic lung transplantation. Dogs were randomly assigned to receive either vehicle (controls) or AT III. We observed that in control dogs, during the 180-minute period after lung transplantation, the arterial O(2) partial pressure decreased and both the alveolar-arterial O(2) difference and the pulmonary vascular resistance increased. By contrast, these parameters remained unchanged in the group of dogs receiving AT III. Dogs with transplants receiving AT III did not show an increase in cell adhesion molecules, and histological examination revealed almost an absence of inflammatory response. The administration of AT III produced a marked increase in serum prostacyclin (PGI(2)) levels, whereas in control dogs, the PGI(2) levels did not change. The beneficial effect of AT III was not observed when dogs received indomethacin to prevent the stimulation of PGI(2) release by AT III.


CONCLUSIONS
Our results demonstrate that AT III prevents ischemia-reperfusion injury in a dog model of lung transplantation and that this effect is conditioned by an increase in PGI(2) production.
Salvatierra
A
A
Servicios de Cirugía Torácica, Hospital Universitario Reina Sofía, Universidad de Córdoba, Spain.
Guerrero
R
R
Rodriguez
M
M
Alvarez
A
A
Soriano
F
F
Lopez-Pedrera
R
R
Ramirez
R
R
Carracedo
J
J
Lopez-Rubio
F
F
Lopez-Pujol
J
J
Velasco
F
F
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D000990:Antithrombin III / Q000378:metabolism / Q000494:pharmacology*; D015815:Cell Adhesion Molecules / Q000096:biosynthesis / Q000187:drug effects; D004285:Dogs; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects; D007213:Indomethacin / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D016040:Lung Transplantation; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control; D013997:Time Factors
D015815:Cell Adhesion Molecules; D015121:6-Ketoprostaglandin F1 alpha; D000990:Antithrombin III; D011464:Epoprostenol; D007213:Indomethacin